Development of a family-community interaction programme in the treatment of women with postpartum depression: protocol for a randomised controlled trial.

INTRODUCTION: Postpartum depression has great harm and becomes a serious public health problem. Most women stay at home after childbirth, so the support from community and family is particularly important in the treatment of postpartum depression. The cooperation between family and community can effectively improve treatment effect of patients with postpartum depression. It is imperative to conduct a study on the collaboration and interaction among patients, family and community in the treatment of postpartum depression. METHODS AND ANALYSIS: The aim of this study is to determine the experience and demands of patients with postpartum depression, family caregivers and community providers for the interaction, construct an interaction intervention programme bettween family and community and promote the rehabilitation of patients with postpartum depression. From September 2022 to October 2022, this study will select postpartum depression patient families from seven communities in Zhengzhou City, Henan Province in China. The researchers, after training, will conduct semi-structured interview to collect research data. According to the integration results of qualitative research and literature review, the interaction intervention programme will be constructed and revised using the Delphi expert consultation method. Then the participants will be selected to accept the intervention of the interaction programme and evaluated through questionnaires. ETHICS AND DISSEMINATION: The study is approved by the Ethics Review Committee of Zhengzhou University (ZZUIRB2021-21). The results of this study will contribute to clarify the responsibilities of family subjects and community subjects in the treatment of postpartum depression, more effectively promote the rehabilitation of patients with postpartum depression and reduce the burden of family and society. Moreover, this research will be a profitable exploration at home and abroad. And the findings will be disseminated through conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: ChiCTR2100045900.